Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Concentration Ganciclovir Eye Drops for CMV Retinitis
NCT05911503Phase 1Recruiting
- Sponsor
- Tianjin Medical University
- Start
- Jul 2023
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ganciclovir in cytomegalovirus retinitis, sponsored by Tianjin Medical University. Primary endpoint: Fundus lesions at 24 weeks. Started Jul 2023; status: recruiting.
02
Drugs
ganciclovir
03
Conditions
cytomegalovirus retinitis
Beyond the preview
Go deeper on NCT05911503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911503.